Medigene expands platform technology with patent for identification of CD4+ T cell antigens
Provides a new source for potential TCR candidates
Advertisement
Medigene AG, a clinical stage immune-oncology company focusing on the development of T cell immuno-therapies for the treatment of cancer, announces the grant of US patent US9,341,617B2. The patent, with an expected life-span until 2030, claims a method for the identification of antigens recognized by CD4+ T cells, including tumor infiltrating CD4+ T cells.
This patent expands Medigene's T-cell receptor (TCR) platform technology with an additional fast and efficient method for the direct identification of antigens and respective epitopes recognized by CD4+ tumor infiltrating lymphocytes and opens the way to identify immune relevant patient-specific neoantigens. Rapid definition of epitopes recognized by CD4+ T helper cells for generation of tumor vaccines also becomes potentially possible.
Prof. Dolores Schendel, CEO and CSO of Medigene, explains: "This newly patented method provides the company with a potential additional source for new TCR candidates and also allows us to identify patient-specific neoantigens seen by CD4+ T cells. While CD4+ tumor infiltrating T cells have been known in the past, finding the antigens for which these T cells are specific was very time-consuming and complex. With the covered method we are now able to overcome these problems and it helps us to provide expanded options for adoptive T-cell therapies with transgenic T-cell receptors."
Medigene holds an exclusive license to the patent that was issued to Helmholtz Zentrum München (German Research Center for Environmental Health). Patents within the same patent family have already been granted in Europe, Australia and Canada.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Researchers combine light and X-ray microscopy for comprehensive insights
Artificial photosynthesis for environmentally friendly food production - Researchers produce important amino acid from greenhouse gas CO₂
Start-ups in Europe: Significant Potential Remains Untapped - Study Shows Differences Between Start-ups in France, Germany and the United Kingdom
Antimicrobial peptides can reduce salmonella in chickens - This discovery could help improve food safety and protect public health without relying on antibiotic use
Corden Pharma International GmbH - Plankstadt, Germany
Novel virtual trade fair for the process industry - A new way to network and stay informed defies postponed or cancelled trade fairs: The "virtual process show" from 8 to 11 September 2020
Bio-concrete from urine - Feasibility study: How to transform urine into a sustainable building material
A sweet defence against lethal bacteria - Synthesising a potential vaccine candidate for an antibiotic-resistant pathogen causing infections in hospitalised patients
Bayer Group: First-quarter performance as expected - “We’re consolidating roles, designing teams for more impact, and taking out layers”
Playing Dominos: How an Artificial Protein Emerges from Fitting Together Individual Components - Open-source tool opens up many different possible applications in biotechnology and medicine
Decoys for Misguided Antibodies Restore Antiviral Immune Defense
